---
title: "LakeShore Biopharma (LSB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LSB.US.md"
symbol: "LSB.US"
name: "LakeShore Biopharma"
industry: "Biotechnology"
datetime: "2026-05-21T16:50:34.691Z"
locales:
  - [en](https://longbridge.com/en/quote/LSB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LSB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LSB.US.md)
---

# LakeShore Biopharma (LSB.US)

## Company Overview

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: C (0.55)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 187 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 7.41% |  |
| Net Profit YoY | 76.90% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 85290264.24 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -18.43% | E |
| Profit Margin | -16.26% | D |
| Gross Margin | 82.47% | A |
| Revenue YoY | 7.41% | C |
| Net Profit YoY | 76.90% | A |
| Total Assets YoY | -10.15% | E |
| Net Assets YoY | -15.11% | E |
| Cash Flow Margin | 121.00% | B |
| OCF YoY | 7.41% | C |
| Turnover | 0.43 | C |
| Gearing Ratio | 63.46% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - LakeShore Biopharma",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "7.41%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "76.90%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "85290264.24",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-18.43%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-16.26%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "82.47%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "7.41%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "76.90%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-10.15%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-15.11%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "121.00%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "7.41%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.43",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "63.46%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.86 | 281/385 | - | - | - |
| PB | 0.38 | 24/385 | 0.38 | 0.38 | 0.38 |
| PS (TTM) | 0.30 | 12/385 | 0.30 | 0.30 | 0.30 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LSB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LSB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LSB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LSB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**